论文部分内容阅读
目的探讨艾迪注射液联合多西紫杉醇治疗中晚期胰腺癌的有效性和安全性。方法采用随机数字表法将160例中晚期胰腺癌患者随机分为对照组和观察组,每组80例。对照组给予多西紫杉醇治疗,观察组给予多西紫杉醇联合使用艾迪注射液治疗,比较两组患者的治疗效果。结果观察组患者近期有效率为58.8%,Karnofsky体力状况(KPS)评分由(60.5±6.3)分增加至(80.9±7.9)分;对照组的近期有效率为33.8%,KPS评分由(61.2±6.8)分增加至(70.3±7.1)分;两组差异均有统计学意义(P<0.05)。观察组患者的不良反应明显少于对照组,白细胞减少、血红蛋白减少及血小板减少的发生率低于对照组(P<0.05)。两组患者恶性呕吐、脱发的发生率差异无统计学意义(P>0.05)。结论艾迪注射液联合多西紫杉醇治疗中晚期胰腺癌可以提高治疗有效率和KPS评分,改善患者生活质量,减少不良反应,值得临床推广。
Objective To investigate the efficacy and safety of Aidi Injection combined with docetaxel in the treatment of advanced pancreatic cancer. Methods 160 patients with advanced pancreatic cancer were randomly divided into control group and observation group with 80 cases in each group. The control group was treated with docetaxel. The observation group was treated with docetaxel combined with Aidi Injection, and the treatment effect was compared between the two groups. Results The effective rate in the observation group was 58.8%, Karnofsky physical condition (KPS) score increased from (60.5 ± 6.3) points to (80.9 ± 7.9) points in the observation group, 33.8% in the control group, and (61.2 ± 6.8) increased to (70.3 ± 7.1) points; the difference between the two groups was statistically significant (P <0.05). Adverse reactions in the observation group were significantly less than those in the control group. The incidences of leukopenia, hemoglobin decrease and thrombocytopenia were lower in the observation group than those in the control group (P <0.05). There was no significant difference in the incidence of malignant vomiting and hair loss between the two groups (P> 0.05). Conclusion Aidi injection combined with docetaxel in the treatment of advanced pancreatic cancer can improve the treatment efficiency and KPS score, improve patient quality of life, reduce adverse reactions, is worth clinical promotion.